Docetaxel (taxotere) in the treatment of prostate cancer.
about
Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cellsThe mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cellsIntratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system.Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.Camalexin-induced apoptosis in prostate cancer cells involves alterations of expression and activity of lysosomal protease cathepsin D.Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism.ST6Gal-I modulates docetaxel sensitivity in human hepatocarcinoma cells via the p38 MAPK/caspase pathway.Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).The phytoalexin camalexin mediates cytotoxicity towards aggressive prostate cancer cells via reactive oxygen species.CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.d -Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis.KIF7 attenuates prostate tumor growth through LKB1-mediated AKT inhibition.
P2860
Q24802917-A30E50EB-EF13-4E63-A91F-5274C289363FQ33676981-69538284-7BF5-4575-9139-320005D3D2C9Q33753357-4235BABD-ADEE-43E5-8D13-5037BDD21853Q35049068-A9990298-BCA5-420C-BD5D-13A9E98B39F5Q35112059-F90EC0E6-AD28-4813-8218-FDB93AF8E2B8Q35224257-DCDB44D8-E511-4347-8079-B74AA8FE41E1Q37463153-C4D1E7FC-9FD7-4C07-B1F2-9B33EE4EF9CDQ37588392-417CB58C-E148-4C98-869D-B682CCD874E3Q38949883-3F8F72A5-1BB3-4912-9992-9E97F86754C6Q38989173-AD043455-7D21-4EA7-98EA-FEC96EA3FA8BQ39239232-4B63656B-05E2-4289-BE82-58F84CCB3AB6Q39782144-16ACFF67-F223-44D0-AF52-A753B3C3E60DQ41292697-C85D92C4-74C5-43C5-94E2-384DB9B58C32Q41551496-A16BE8E1-0390-4043-9E0E-E2C0D8B22C02
P2860
Docetaxel (taxotere) in the treatment of prostate cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Docetaxel (taxotere) in the treatment of prostate cancer.
@ast
Docetaxel (taxotere) in the treatment of prostate cancer.
@en
type
label
Docetaxel (taxotere) in the treatment of prostate cancer.
@ast
Docetaxel (taxotere) in the treatment of prostate cancer.
@en
prefLabel
Docetaxel (taxotere) in the treatment of prostate cancer.
@ast
Docetaxel (taxotere) in the treatment of prostate cancer.
@en
P2093
P2860
P356
P1476
Docetaxel (taxotere) in the treatment of prostate cancer.
@en
P2093
Kristine M Eilers
Mohammed El-Geneidi
Tomasz M Beer
P2860
P304
P356
10.1586/14737140.3.3.261
P577
2003-06-01T00:00:00Z